Treatment of Inflammatory Myopathy

Initial Treatment Protocol

• The American College of Physicians recommends starting prednisone at 0.5-1 mg/kg/day for 2-4 weeks concurrent with a steroid-sparing immunosuppressive agent from day one, as corticosteroid monotherapy fails in 86% of patients 1
• Higher doses of prednisone (closer to 1 mg/kg) should be used for patients at high risk of relapse and low risk of adverse events, according to the Mayo Clinic Proceedings 2, 1
• Lower doses of prednisone (closer to 0.5 mg/kg) should be used for patients with diabetes, osteoporosis, or glaucoma, as recommended by the Mayo Clinic Proceedings 2, 1
• Administer prednisone as a single daily dose for 2-4 weeks before beginning taper, as suggested by the Mayo Clinic Proceedings 2, 1
• For severe weakness, dysphagia, or respiratory muscle involvement, add IV methylprednisolone 10-20 mg/kg for 1-5 consecutive days, according to the Mayo Clinic Proceedings 3, 4

Mandatory Concurrent Steroid-Sparing Agent

• Methotrexate is the first-line treatment for most patients without lung disease, with a starting dose of 15 mg orally once weekly and 1 mg/day folic acid supplementation, as recommended by the Mayo Clinic Proceedings 2, 1
• Azathioprine is preferred for interstitial lung disease or pregnancy planning, with a target dose of 2 mg/kg ideal body weight, according to the Mayo Clinic Proceedings 2, 4
• Mycophenolate mofetil is preferred for severe dermatomyositis skin disease, with a starting dose of 500 mg twice daily, as suggested by the Mayo Clinic Proceedings 2, 1

Systematic Prednisone Tapering Schedule

• Begin tapering prednisone after 2-4 weeks based on clinical response, with a tapering schedule of 60 mg/day to 0 mg/day over several weeks, as recommended by the Mayo Clinic Proceedings 2, 1

Treatment for Severe or Refractory Disease

• Intravenous Immunoglobulin (IVIG) is indicated for dysphagia, notable weight loss, severe rash, or weakness, with a dose of 1-2 g/kg ideal body weight over 2 consecutive days, according to the Mayo Clinic Proceedings 2
• Rituximab is effective for refractory disease, with two 1000-mg doses given 2 weeks apart for adults, as suggested by the Mayo Clinic Proceedings 3
• Cyclophosphamide is used for severe ILD or refractory disease, with infusions given every 4 weeks for 3-6 months, according to the Mayo Clinic Proceedings 3

Pediatric Dosing

• Prednisone should be started at 2 mg/kg/day up to a maximum of 60 mg/day for juvenile dermatomyositis, as recommended by the Mayo Clinic Proceedings 3, 1
• Subcutaneous methotrexate should be started at 15 mg/m² once weekly from treatment onset, according to the Mayo Clinic Proceedings 3, 1

Critical Monitoring Requirements

• Regular muscle strength testing and creatine kinase levels should be monitored, as recommended by Praxis Medical Insights 1, 5
• Functional capacity and activities of daily living assessments should be performed, according to Praxis Medical Insights 4
• MRI with T2-weighted and fat suppression sequences should be used to assess muscle inflammation, as suggested by Praxis Medical Insights 4, 5

Special Populations

• Anti-HMGCR-associated myopathy requires aggressive combination therapy from the outset, with a mandatory concurrent immunosuppression, according to Praxis Medical Insights 4
• Immune-mediated necrotizing myopathy may require more aggressive immunosuppression, as suggested by Praxis Medical Insights 5

Management of Mycophenolate Mofetil Treatment for Dermatomyositis and Myopathy

Introduction to Treatment Duration

• Patients with dermatomyositis and myopathy can remain on mycophenolate mofetil (MMF) indefinitely as long as disease control is maintained, but withdrawal should be considered only after achieving remission for a minimum of 1 year off corticosteroids, according to the European League Against Rheumatism 6

Treatment Duration Framework

• Continue MMF for at least 1 year after achieving complete disease remission off corticosteroids before attempting to discontinue the medication, as recommended by the American College of Rheumatology 6
• MMF can be continued as long-term maintenance therapy for years if needed to maintain disease control, particularly in patients with severe or refractory disease, as suggested by the Mayo Clinic 7, 8

Long-Term Maintenance Therapy

• The typical maintenance dose is 1000 mg twice daily (2 g/day total), though some patients may require up to 1500 mg twice daily (3 g/day total), according to the Mayo Clinic 7, 8
• Initial clinical response typically occurs within 4-8 weeks of starting MMF, though full efficacy may take 3-6 months, as reported by the Mayo Clinic 7, 8

Monitoring During Long-Term Treatment

• Monitor complete blood count and liver function tests regularly to detect leukopenia or transaminitis, as recommended by the American Academy of Dermatology 7, 8, 9
• Check for gastrointestinal side effects (nausea, loose stools), which are the most common adverse effects and may require dose adjustment or switching to enteric-coated mycophenolic acid, according to the Journal of the American Academy of Dermatology 7, 9

Disease Activity Assessment

• Monitor creatine kinase levels, though these may not always correlate with disease activity, as noted by the Annals of the Rheumatic Diseases 6

Corticosteroid-Sparing Effect

• MMF allows significant reduction in prednisone dose, which is its primary benefit as a steroid-sparing agent, as reported by the Mayo Clinic 7, 8
• The goal is to taper corticosteroids to the lowest possible dose or discontinue them entirely while maintaining disease control with MMF, according to the Mayo Clinic 7, 8

Special Considerations for Withdrawal

• Disease must be in complete remission for minimum 1 year off corticosteroids before attempting MMF withdrawal, as recommended by the European League Against Rheumatism 6
• Patient should have normal muscle strength (Manual Muscle Test-8 score of 80/80) before attempting MMF withdrawal, according to the Annals of the Rheumatic Diseases 6

Critical Pitfalls to Avoid

• Never discontinue MMF while patient is still on corticosteroids or has active disease, as this will likely result in disease flare, as warned by the Annals of the Rheumatic Diseases 6
• Do not stop MMF abruptly without a plan for monitoring, as disease relapse may occur weeks to months after discontinuation, according to the Annals of the Rheumatic Diseases 6
• Avoid premature discontinuation before 1 year of remission off steroids, as this increases relapse risk, as noted by the Annals of the Rheumatic Diseases 6
• Do not continue MMF indefinitely without periodic reassessment of whether the medication is still necessary, particularly if patient has been in remission for extended periods, as recommended by the Annals of the Rheumatic Diseases 6